Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes

    Four-month study detailing effects of treatment of HIV-positive
    individuals with American Biotech Labs (ABL) ASAP 10 treatment indicates
    significant improvement in the condition of the subjects after treatment;
    in-vitro laboratory work shows that ABL nanosilver particles can block
    entry of the virus into cells, "eventually destroying the virus"

    ALPINE, UT, Aug. 29 /CNW/ - American Biotech Labs, developer of a new
class of products based on the company's patented nano-catalytic SilverSol
Technology(TM), today announced that a preliminary study of the effect of the
company's ASAP 10 treatment on HIV-positive individuals has been published in
the first issue of the Journal of the Science of Healing Outcomes (JSHO; JSHO is a scholarly health journal that
publishes compelling new medical research data and reports.
    The study was conducted over four months with seven HIV-positive
patients, each of whom was administered 15 ml of ABL ASAP 10 ppm (parts per
million) four times daily. As a result of the ABL treatment, "Clinically, (the
patients) were 100 percent fit and were feeling much better after the
treatment period," said Dr. B.M. Hegde, world-renowned cardiologist and editor
of JSHO.
    During the course of the therapy, the patients experienced an average
body weight gain of eight kilograms (17.6 pounds) and an average T-lymphocyte
count increase of 180 per micro-liter (39.52 percent).
    One of the study's most significant findings, said Hegde, was the effect
of ABL ASAP on HIV, the AIDS-causing virus. "Our recent laboratory work of the
effect of nano silver in vitro on the... virus did show that the nanosilver
particles could bind to (HIV) and could potentially block the viral entry into
cells, eventually destroying the virus."
    Hegde added, "Now that we have the laboratory results of the drug's
efficacy and safety, we are planning a large scale controlled study of the
application to HIV positive individuals in the near future."

    About American Biotech Labs

    American Biotech Labs (ABL;, founded in
1998, utilizes patented processes and SilverSol Technology(TM) to create
singularly powerful and effective nano-catalytic silver products. In extensive
testing performed by a variety of respected laboratories and researchers,
ABL's silver hydrosol has consistently demonstrated the ability, without any
known toxic side effects, to destroy a wide range of bacteria, viruses, yeast,
and molds. ABL products have been approved by the U.S. EPA as a disinfectant
for dental water lines, and as a surface disinfectant for bacteria, yeast and
mold in hospital, residential, commercial and industrial settings. The
company's products are sold worldwide at health food stores and by medical
professionals under the Silver Biotics(R) and ASAP Solution(R) brands and
through a variety of private labels.

For further information:

For further information: Press Contact: Kimball Thomson, Next Phase
Communications (for American Biotech Labs), (801) 918-3637,

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890